has signed an agreement worth more than $1.3 billion with US pharmaceutical giant Eli Lilly & Co. to license out its novel RNA-editing technology to jointly develop therapies for sensorineural hearing ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...